Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium

PURPOSE: To determine the dose of cetuximab that can be safely combined with irinotecan for treatment of pediatric and adolescent patients with refractory solid tumors. PATIENTS AND METHODS: This open-label, phase I study enrolled patients ages 1 to 18 years with advanced refractory solid tumors, in...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Trippett, Tanya M., Herzog, Cynthia, Whitlock, James A., Wolff, Johannes, Kuttesch, John, Bagatell, Rochelle, Hunger, Stephen P., Boklan, Jessica, Smith, Amy A., Arceci, Robert J., Katzenstein, Howard M., Harbison, Christopher, Zhou, Xiaofei, Lu, Haolan, Langer, Christiane, Weber, Martin, Gore, Lia
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2009
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5321093/
https://ncbi.nlm.nih.gov/pubmed/19770383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.8975
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia